Co-Diagnostics Inc. logo

Co-Diagnostics Inc. (C97)

Market Closed
8 Dec, 20:00
0. 30
-0.02
-7.41%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-0.9 Eps
0.32
Previous Close
Day Range
0.3 0.32
Year Range
0.2 1.02
Want to track C97 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

C97 closed today lower at €0.3, a decrease of 7.41% from yesterday's close, completing a monthly decrease of -25.74% or €0.1. Over the past 12 months, C97 stock lost -58.62%.
C97 is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, exceeded the consensus estimates by 0.19%. On average, the company has surpassed earnings expectations by 0.06%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

C97 Chart

CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know

CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 6 days ago
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript

Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript

Co-Diagnostics, Inc. ( CODX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Company Secretary Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.

Seekingalpha | 3 weeks ago
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.32 per share a year ago.

Zacks | 3 weeks ago

Co-Diagnostics Inc. (C97) FAQ

What is the stock price today?

The current price is €0.30.

On which exchange is it traded?

Co-Diagnostics Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is C97.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has Co-Diagnostics Inc. ever had a stock split?

No, there has never been a stock split.

Co-Diagnostics Inc. Profile

Biotechnology Industry
Healthcare Sector
Dwight H. Egan CEO
XBER Exchange
US1897631057 ISIN
US Country
132 Employees
- Last Dividend
- Last Split
12 Jul 2017 IPO Date

Overview

Co-Diagnostics, Inc. is a pioneering molecular diagnostics company that engages in the development, manufacturing, and sale of reagents used for tests that function via the detection and/or analysis of nucleic acid molecules. Operating both in the United States and internationally, the company has carved a niche for itself in the field of diagnostic tests, focusing on a wide array of infectious diseases. Established in 2013 and based in Salt Lake City, Utah, Co-Diagnostics, Inc. has expanded its footprint globally, offering an extensive array of diagnostic solutions catering to several health concerns and industries. The company's commitment to innovation is evident in its offering of advanced molecular tools for the detection of infectious diseases, agricultural applications, and more.

Products and Services

Co-Diagnostics, Inc. offers an extensive range of products and services aimed at providing diagnostic solutions and advancing the field of molecular diagnostics. These include:

  • Polymerase Chain Reaction (PCR) Diagnostic Tests: The company specializes in PCR diagnostic tests for a number of infectious diseases such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. These tests play a crucial role in the early detection and management of infectious diseases globally.
  • Multiplexed Tests: Co-Diagnostics provides three multiplexed tests designed for testing mosquitos to identify various diseases they carry. This innovative approach aids in controlling and preventing the spread of mosquito-borne diseases.
  • Molecular Tools: A wide range of molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications are part of their offerings. These tools facilitate the accurate and timely diagnosis of diseases, contributing to better patient outcomes and agricultural productivity.
  • Genetic Trait Identification Tests: The company offers tests that identify genetic traits in plant and animal genomes. This technology supports advancements in agriculture and livestock breeding by enabling the selection of desirable traits.
  • Portable PCR Device: Co-Diagnostics has developed a portable PCR device designed to bring PCR diagnostic capabilities to patients in point-of-care and at-home settings. This innovation enhances access to diagnostic tests, making it convenient for users to receive timely health assessments.
  • Diagnostic Equipment Sales: In addition to its proprietary diagnostic tests and devices, Co-Diagnostics intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. This expansion allows the company to offer comprehensive diagnostic solutions to its clients.

Contact Information

Address: 2401 South Foothill Drive
Phone: 801 438 1036